CA2929937C - Hiv-1 envelope proteins and fragments thereof that possess epitopes recognized by broadly neutralizing antibodies - Google Patents

Hiv-1 envelope proteins and fragments thereof that possess epitopes recognized by broadly neutralizing antibodies Download PDF

Info

Publication number
CA2929937C
CA2929937C CA2929937A CA2929937A CA2929937C CA 2929937 C CA2929937 C CA 2929937C CA 2929937 A CA2929937 A CA 2929937A CA 2929937 A CA2929937 A CA 2929937A CA 2929937 C CA2929937 C CA 2929937C
Authority
CA
Canada
Prior art keywords
fragment
hiv
binding
rgp120
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2929937A
Other languages
English (en)
French (fr)
Other versions
CA2929937A1 (en
Inventor
Phillip W. Berman
Gwen Tatsuno
Bin Yu
Javier Morales
Kathryn Mesa
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CA2929937A1 publication Critical patent/CA2929937A1/en
Application granted granted Critical
Publication of CA2929937C publication Critical patent/CA2929937C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2929937A 2012-09-11 2013-09-11 Hiv-1 envelope proteins and fragments thereof that possess epitopes recognized by broadly neutralizing antibodies Expired - Fee Related CA2929937C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261699680P 2012-09-11 2012-09-11
US61/699,680 2012-09-11
PCT/US2013/059243 WO2014043220A2 (en) 2012-09-11 2013-09-11 Hiv-1 envelope proteins and fragments thereof that possess epitopes recognized by broadly neutralizing antibodies

Publications (2)

Publication Number Publication Date
CA2929937A1 CA2929937A1 (en) 2014-03-20
CA2929937C true CA2929937C (en) 2020-01-07

Family

ID=50278843

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2929937A Expired - Fee Related CA2929937C (en) 2012-09-11 2013-09-11 Hiv-1 envelope proteins and fragments thereof that possess epitopes recognized by broadly neutralizing antibodies

Country Status (7)

Country Link
US (2) US9731002B2 (https=)
EP (1) EP2928492A4 (https=)
CN (1) CN106170296A (https=)
AU (1) AU2013315631B2 (https=)
CA (1) CA2929937C (https=)
IN (1) IN2015DN03026A (https=)
WO (1) WO2014043220A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2739300B1 (en) 2011-07-05 2019-06-19 Duke University N-terminal deleted gp120 immunogens
CA2850745C (en) 2011-10-03 2022-12-13 Duke University Vaccine
WO2017023857A1 (en) * 2015-08-01 2017-02-09 The Regents Of The University Of California Polypeptide glycopeptide fragments from the v1/v2 and v3 domains of the hiv-1 envelope protein gp 120
CN106800603B (zh) * 2017-01-24 2020-07-28 中国食品药品检定研究院 检测抗hiv抗体的adcc活性的方法
WO2019018310A1 (en) * 2017-07-19 2019-01-24 The Regents Of The University Of California MGAT1-IMPROVED CELLS FOR THE PRODUCTION OF VACCINES AND BIOPHARMACEUTICAL PRODUCTS
EP3866860B1 (en) * 2018-10-15 2025-01-08 The Regents Of The University Of California Complement component 1s (c1s) deficient cells for production of vaccines and biopharmaceutical proteins
WO2020117740A1 (en) * 2018-12-03 2020-06-11 International Aids Vaccine Initiative Recombinant hiv env polypeptides and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6268199A (en) * 1998-09-29 2000-04-17 University Of Kansas Medical Center Live virus vaccines to protect primates from hiv-1 infection and disease
WO2005097822A1 (en) * 2004-04-09 2005-10-20 University Of Manitoba Identification of the precise amino acid sequence of the epitope recognized by the potent neutralizing human anti-hiv-1 monoclonal antibody igg1b12
US9782472B2 (en) 2008-10-04 2017-10-10 The Regents Of The University Of California Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity
US9034341B2 (en) * 2009-04-20 2015-05-19 Transtech Pharma, Llc Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions
US8715685B2 (en) * 2009-07-14 2014-05-06 Lucia Irene Gonzalez Stereoisomer peptides and their polymer conjugates for HIV disease
US20130101617A1 (en) * 2010-06-30 2013-04-25 Torrey Pines Institute For Molecular Studies Env trimer immunogens
CA2858347C (en) 2011-12-05 2020-07-07 New York University V1v2 immunogens

Also Published As

Publication number Publication date
AU2013315631B2 (en) 2018-04-19
US10507239B2 (en) 2019-12-17
IN2015DN03026A (https=) 2015-10-02
EP2928492A4 (en) 2017-09-13
AU2013315631A1 (en) 2015-04-30
EP2928492A2 (en) 2015-10-14
US9731002B2 (en) 2017-08-15
US20150246111A1 (en) 2015-09-03
US20180036401A1 (en) 2018-02-08
WO2014043220A2 (en) 2014-03-20
CN106170296A (zh) 2016-11-30
WO2014043220A3 (en) 2016-10-27
CA2929937A1 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
US10507239B2 (en) V1/V2 fragments of a HIV-1 envelope glycoprotein
US20230190910A1 (en) Scaffolded hiv-1 vaccine immunogens
US10058604B2 (en) Soluble HIV-1 envelope glycoprotein trimers
JP2003529319A (ja) ＨＩＶ−１ｇｐ４１を標的化する広範に中和する抗体を誘発する方法
EP2073840A2 (en) Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
WO2013039792A1 (en) Immunogens based on an hiv-1 gp120 v1v2 epitope
JP2012500829A (ja) Ｃｂｄ１エピトープにおけるオーバーラップする中和決定基に対応する合成ペプチドによって広域中和抗体が誘導される
JP2015521592A (ja) 安定化されたｇｐ１２０
Pinter Roles of HIV-1 Env variable regions in viral neutralization and vaccine development
AU2020367242B2 (en) Influenza virus vaccines and uses thereof
US9707290B2 (en) Immunogens of HIV-1 broadly neutralizing antibodies, methods of generation and uses thereof
Du et al. Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein
CN1930184B (zh) 新型tat复合物，及包含其的疫苗
Cruz et al. Enhanced immunogenicity and cross-reactivity of HIV-1 V3-peptide and multiple antigen peptides conjugated to distinct carrier proteins
WO2017023857A1 (en) Polypeptide glycopeptide fragments from the v1/v2 and v3 domains of the hiv-1 envelope protein gp 120
CA2509387A1 (en) Peptide oligomers for use as hiv vaccines
Morales V1/V2 domain scaffolds to improve the magnitude and quality of protective antibody responses to HIV-1
Peterhoff et al. Lisa Rogers 3, 4, Georgios Pollakis 6, 7, Paul Tonks 2, Michael Hoelscher 3, 4, Song Ding 8, Rogier W. Sanders 9, 10, Christof Geldmacher 3, 4, Quentin Sattentau 11, Winfried Weissenhorn 5, Jonathan L. Heeney 2

Legal Events

Date Code Title Description
MKLA Lapsed

Effective date: 20220311

MKLA Lapsed

Effective date: 20200911